Zopiclone → Eszopiclone
Reaction equation
[CH3:1][N:2]1[CH2:7][CH2:6][N:5]([C:8]([O:10][CH:11]2[N:20]([C:21]3[CH:22]=[CH:23][C:24]([Cl:27])=[CH:25][N:26]=3)[C:18](=[O:19])[C:13]3[N:14]=[CH:15][CH:16]=[N:17][C:12]2=3)=[O:9])[CH2:4][CH2:3]1.C(OC(=O)C(C(C(OC(=O)C1C=CC=CC=1)=O)O)O)(=O)C1C=CC=CC=1>C(Cl)Cl>[CH3:1][N:2]1[CH2:7][CH2:6][N:5]([C:8]([O:10][C@@H:11]2[N:20]([C:21]3[CH:22]=[CH:23][C:24]([Cl:27])=[CH:25][N:26]=3)[C:18](=[O:19])[C:13]3[N:14]=[CH:15][CH:16]=[N:17][C:12]2=3)=[O:9])[CH2:4][CH2:3]1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
Accordingly, racemic zopiclone is preferably reacted with a resolving agent (+)-O,O′-dibenzoyl tartaric acid in methylene dichloride at room temperature to obtain the diastereomeric salt (Scheme IV) which is crystallized from acetonitrile followed by conversion into eszopiclone by treating with an inorganic base, such as NaOH. Eszopiclone thus obtained has a purity above 99%. Eszopiclone is recrystallized from ethyl acetate to obtain the product with purity of 99.9%
Workup
- customto obtain the diastereomeric salt (Scheme IV) which
- customis crystallized from acetonitrile
- additionby treating with an inorganic base, such as NaOH
Sources & evidence
- ORD record
- ord-2cbdcbc8be4a42369650ca5dc097ab87
- Source dataset
- uspto-grants-2010_08
- Patent number
- US07786304B2
Reaction notes
Loading…